Methyl (S)-2-(Boc-amino) -3-[(S)-2-oxo-3-pyrrolidinyl] propanoate CAS 328086-60-8 PF-07321332 Boceprevir Intermedia
Commercial Supple PF-07321332 Paxlovid Intermedia cum High Quality
L-tert-Leucine (H-Tle-OH) CAS 20859-02-3
Caronic Anhydride CAS 67911-21-1
(1R,2S,5S)-6,6-Dimethyl-3-azabicyclo[3.1.0]hexane-2-Carboxylic Acid Methyl Ester Hydrochloride 565456-77-1
Methyl(S)-2-(Boc-amino)-3-[(S)-2-oxo-3-pyrrolidinyl]propanoate CAS 328086-60-8
6,6-Dimethyl-3-azabicyclo[3.1.0]hexane CAS 943516-54-9
Nomen chemicum | Methyl (S) -2-(Boc-amino) -3-[(S)-2-oxo-3-pyrrolidinyl]propanoate |
Synonyma | Methyl (S) -2-((tert-butoxycarbonyl)amino)-3-((S)-2-oxopyrrolidin-3-yl)propanoate;(αS,3S)-α-[(tert-Butyloxycarbonyl)aMino]-2-oxo-3-pyrrolidinepropanoic acid Methyl Ester;(S)-Methyl 2-((tert-butoxycarbonyl) amino) 3-((S)-2-oxopyrrolidin-3-yl) propanoate |
CAS Number | 328086-60-8 |
CATTUS Number | RF-PI317 |
Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
Formulae hypotheticae | C13H22N2O5 |
M. Pondus | 286.33 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad Off-White pulveris |
Lepidium sativum | IR: Similia Reference substantia |
Lepidium sativum B * | Retention tempus: Similia Reference substantia |
Damnum in Siccatio | ≤1.0% |
Residere in Ignition | ≤0.20% |
una immunditia | ≤0.50% |
Totalis immunditias | ≤2.0% |
Metalla gravia (Pb) | ≤20ppm |
Puritas | ≥98.0% |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedium PF-07321332 Paxlovid (CAS 2628280-40-8) et Boceprevir (CAS 394730-60-0); |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Methyl (S)-2-(Boc-amino) -3-[(S)-2-oxo-3-pyrrolidinyl] propanoate (CAS 328086-60-8) medium est PF-07321332 Paxlovid (CAS 2628280-40 -8) et Boceprevir (CAS 394730-60-0).PF-07321332, pars cardinis Paxlovid (PF-07321332 et Ritonavir) quae est candidatus investigationis COVID-19 oralis antiviralis, ore protease est 3C-similis protease (3CLPRO) inhibitor cum effectibus antiviralibus potentibus contra virum SARS-CoV-2 et COVID-XIX.Die 6 Nove 2021, Pfizer denuntiavit Paxlovid signanter hospitalizationem et mortem reductam, innixam analysi interim Phase 2/3 EPIC-HR (Aestimatio Proteasis Inhibitionis pro COVID-19 in aegroti High-Risk) temere, duplex studium caecum. de aegris adultis non hospitalitatis apud COVID-19, qui in magno periculo sunt progrediendi ad gravem morbum.Boceprevir (EBP-520) est inhibitor HCV protease (Ki=14 nM) ad infectio viri curationem hepatitis C.Boceprevir cum interferone et ribavirino pegylato (PegIFN/RBV) emendationem fecit in responsionis virologicis patientibus cum genotype 1 HCV.Boceprevir commercium cum therapia immunosuppressiva (IT) inhibendo cytochroma P450 3A enzyme.